drugset / Trial / NCT05904470
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.
Timeline
- Start
- 2023-05-30
- Primary completion
- 2024-12-09
- Completion
- 2025-01-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemnifosbuvir | Other / unclassified | 550 mg | Oral |
| Subject | Ruzasvir | Other / unclassified | 180 mg | Oral |